Skip to main content

Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Summary

The aim was to evaluate long-term graft survival and function after conversion to sirolimus (SRL) for chronic calcineurin inhibitor (CNI) toxicity and the predictive value of baseline proteinuria. This is a follow-up conversion study of 59 renal transplant patients with deteriorating graft function and histologic signs of CNI toxicity. Previously, baseline proteinuria <800 mg/day was identified as a short-term predictor for successful conversion. Follow-up was 5.3 ± 0.8 (3.7–6.8) years. Patient survival was 88%, graft survival 38%. Creatinine clearance at the last follow-up was 33.7 ± 14 ml/min, proteinuria 826 ± 860mg/day. Baseline proteinuria <800 mg/day was associated with better graft survival. In a cox analysis including proteinuria >800 mg, glomerular filtration rate, age at conversion, chronic Banff score at conversion and time after transplantation at conversion, higher proteinuria was associated with a relative risk of graft loss of 3.98. Prognosis of chronic allograft dysfunction is poor. However, conversion to SRL remains an option for patients with low baseline proteinuria, which can slow down deterioration of graft function during a follow-up period of up to 5 years.

Keywords: calcineurin inhibitor; chronic allograft dysfunction; mammalian target of rapamycin inhibitor; proteinuria; rapamycin; sirolimus; toxicity

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1432-2277.2007.00592.x

Affiliations: 1:  Department of Nephrology, Charité Campus Mitte, Berlin, Germany 2:  Department of Nephrology and Renal Transplantation, Hospital Clínic, Barcelona, Spain

Publication date: 2008-02-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more